1. Pink Sheet
  2. >>Market Access

HHS Secretary Alex Azar Talks Rebate Changes, But Not Eliminating Discounts Altogether

 
• By Jessica Merrill

Details on anticipated changes to rebate practices are in demand. HHS Secretary Azar talked about changes that would still allow negotiated discounts at the point of sale during a presentation at the FT Pharma Pricing and Value Summit.

United States Secretary of Health and Human Service, Alex Azar, speaks at the FT Pharma Pricing and Value Summit in New York
HHS Secretary Alex Azar at the FT Pharma Pricing and Value Summit • Source: FT Live

HHS Secretary Alex Azar reaffirmed that drug rebate changes are coming, during an address at the FT Pharma Pricing and Value Summit Sept. 13, but he did not mention eliminating discounts altogether.

The pharmaceutical industry is in a whirlwind about rebates, preparing for a future that is expected to include big changes to the long-standing practice industry relies on to negotiate market...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 
• By Derrick Gingery

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.